Allergen immunotherapy (AIT) for the multiple-pollen sensitive patient

Area of Science:

• Allergology and Immunology
• Clinical Medicine

Background:

• Most individuals with allergies are polysensitized, meaning they react to multiple allergens.
• Current allergy immunotherapy (AIT) practices differ between Europe and the U.S. for polysensitized patients.
• The U.S. typically prescribes AIT covering all identified allergen sensitivities, while Europe often focuses on the single most problematic allergy.

Purpose of the Study:

• To review the evidence supporting the U.S. approach to AIT for polysensitized patients.
• To discuss the impact of component-resolved diagnosis (CRD) on managing polysensitized individuals.
• To highlight advancements in understanding and treating complex allergic sensitivities.

Main Methods:

• Review of existing clinical evidence and practice guidelines for allergy immunotherapy.
• Analysis of the role and application of component-resolved diagnosis (CRD) in allergy management.
• Expert commentary on the interpretation of CRD results for polysensitized patients.

Main Results:

• Evidence supports the U.S. practice of including all allergen extracts in AIT for polysensitized patients.
• Component-resolved diagnosis (CRD) is a significant advancement in managing polysensitized patients.
• CRD helps differentiate between specific allergen sensitization and cross-reactivity due to panallergens.

Conclusions:

• The U.S. approach to AIT for polysensitized patients is evidence-based.
• Component-resolved diagnosis (CRD) offers improved diagnostic precision for complex allergies.
• Understanding allergen-specific sensitization versus cross-reactivity is crucial for effective AIT.